Skip to main content
. 2016 Apr 1;241(14):1577–1587. doi: 10.1177/1535370216643418

Figure 1.

Figure 1

Effects of doxorubicin (DOX) with/without sitagliptin (Sita) pretreatment on serum cardiotoxicity markers. (a) CK-MB: creatine kinase-MB, (b) LDH: lactate dehydrogenase. Data are the mean ± SEM (n = 8).**P < 0.01, ***P < 0.001 significantly different as compared to the control. #P < 0.05, ###P < 0.001 significantly different as compared to the DOX group (ANOVA followed by Tukey-Kramer multiple comparison as a post-hoc test)